Thierry Passeron

Guidelines for the management of vitiligo: the European Dermatology Forum consensus

Agustı́n Alomar, Markus Böhm, Maria Lucia Dell’Anna et al. · British Journal of Dermatology · 2012 · 436 citations

Treatment Guidelines, Pathogenesis, S1 Level +8

Melanocytes Sense Blue Light and Regulate Pigmentation through Opsin-3

Claire Regazzetti, Laura Sormani, Delphine Debayle et al. · Journal of Investigative Dermatology · 2017 · 315 citations

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

Alexa B. Kimball, Gregor B. E. Jemec, Afsáneh Alavi et al. · The Lancet · 2023 · 270 citations

Inflammation, Double-blind Phase 3, Week 16 +5

Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance

Michaël Cerezo, Abdelali Lehraiki, Antoine Millet et al. · Cancer Cell · 2016 · 251 citations · Full text

Medicine, Photocarcinogenesis, Melanoma +6

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo

David Rosmarin, Thierry Passeron, Amit G. Pandya et al. · New England Journal of Medicine · 2022 · 232 citations